HC Wainwright Has Bearish Forecast for ONCY FY2029 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Stock analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.73 for the year, down from their previous forecast of $0.75. HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share.

Several other equities analysts have also recently weighed in on ONCY. Royal Bank of Canada decreased their price objective on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Monday. Leede Financial downgraded Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Finally, Maxim Group decreased their target price on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday. Three analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Trading Up 2.8 %

Oncolytics Biotech stock opened at $0.63 on Wednesday. Oncolytics Biotech has a 1-year low of $0.58 and a 1-year high of $1.53. The company has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $0.92. The company has a market cap of $53.87 million, a P/E ratio of -2.33 and a beta of 1.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after acquiring an additional 24,997 shares during the period. National Bank of Canada FI raised its position in shares of Oncolytics Biotech by 199.6% in the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after purchasing an additional 42,955 shares during the period. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech during the 4th quarter worth about $90,000. Vantage Point Financial LLC bought a new stake in shares of Oncolytics Biotech during the 4th quarter worth about $27,000. Finally, International Assets Investment Management LLC boosted its holdings in shares of Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after buying an additional 26,069 shares during the period. 6.82% of the stock is currently owned by institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.